Format

Send to

Choose Destination
Immunity. 2013 Aug 22;39(2):357-71. doi: 10.1016/j.immuni.2013.07.018. Epub 2013 Aug 15.

Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis.

Author information

1
Medical Department 1, Friedrich-Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany.

Abstract

Liver fibrosis is a consequence of chronic liver diseases and thus a major cause of mortality and morbidity. Clinical evidence and animal studies suggest that local tissue homeostasis is disturbed due to immunological responses to chronic hepatocellular stress. Poorly defined stress-associated inflammatory networks are thought to mediate gradual accumulation of extracellular-matrix components, ultimately leading to fibrosis and liver failure. Here we have reported that hepatic expression of interleukin-33 (IL-33) was both required and sufficient for severe hepatic fibrosis in vivo. We have demonstrated that IL-33's profibrotic effects related to activation and expansion of liver resident innate lymphoid cells (ILC2). We identified ILC2-derived IL-13, acting through type-II IL-4 receptor-dependent signaling via the transcription factor STAT6 and hepatic stellate-cell activation, as a critical downstream cytokine of IL-33-dependent pathologic tissue remodeling and fibrosis. Our data reveal key immunological networks implicated in hepatic fibrosis and support the concept of modulation of IL-33 bioactivity for therapeutic purposes.

PMID:
23954132
PMCID:
PMC4172965
DOI:
10.1016/j.immuni.2013.07.018
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center